Publication Date
10-1-2024
Journal
Clinical Kidney Journal
DOI
10.1093/ckj/sfae295
PMID
39464260
PMCID
PMC11503019
PubMedCentral® Posted Date
9-30-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
chronic kidney disease, heart failure, hyperkalaemia management, RAASi, real-world evidence
Abstract
BACKGROUND: Guideline-recommended hyperkalaemia management includes dietary potassium (K
METHODS: This study enrolled participants within 21 days of an episode of hyperkalaemia in four European countries (UK, Spain, Germany, Italy) and the USA. During the 12-month follow up, data collected will include participant and healthcare provider characteristics (specialty and practice setting), hyperkalaemia treatment objectives and strategies, rationale for management decisions and indicators of response and patient-reported perceptions of their hyperkalaemia treatment.
RESULTS: The enrolled cohort includes 1330 participants, mean age 68 years, of whom 31% were women. At baseline, 6% reported heart failure, 55% chronic kidney disease, 29% both and 9% neither. Most participants (57%) were taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor/neprilysin inhibitor at baseline. Mineralocorticoid receptor antagonist use was lower (14%).
CONCLUSIONS: The prospective TRACK study will shed light on practitioners' hyperkalaemia management decision-making and assess the impact of their decisions on hyperkalaemia recurrence. Understanding practitioners' underlying thought processes will facilitate efforts to improve hyperkalaemia management.ClinicalTrials.gov: NCT05408039.
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Medical Sciences Commons, Nephrology Commons
Comments
ClinicalTrials.gov: NCT05408039
Associated Data